Context Therapeutics Inc. financial data

Symbol
CNTX on Nasdaq
Location
Philadelphia, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2340% % 16%
Debt-to-equity 4.5% % -14%
Return On Equity -31% % 47%
Return On Assets -30% % 47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91,879,177 shares 23%
Common Stock, Shares, Outstanding 91,879,177 shares 23%
Entity Public Float $148,200,000 USD 523%
Common Stock, Value, Issued $91,879 USD 23%
Weighted Average Number of Shares Outstanding, Basic 95,185,187 shares 18%
Weighted Average Number of Shares Outstanding, Diluted 95,185,187 shares 18%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $7,674,393 USD 8.7%
Operating Income (Loss) $30,208,407 USD 7.2%
Nonoperating Income (Expense) $66,306 USD -1979%
Net Income (Loss) Attributable to Parent $26,440,916 USD 12%
Earnings Per Share, Basic 0 USD/shares 77%
Earnings Per Share, Diluted 0 USD/shares 77%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $76,938,183 USD -9.3%
Assets, Current $79,058,817 USD -8.1%
Property, Plant and Equipment, Net $33,721 USD 126%
Operating Lease, Right-of-Use Asset $138,622 USD -43%
Assets $79,231,160 USD -8.2%
Accounts Payable, Current $2,720,876 USD 165%
Employee-related Liabilities, Current $1,091,602 USD 74%
Accrued Liabilities, Current $3,195,918 USD 167%
Liabilities, Current $6,035,774 USD 159%
Operating Lease, Liability, Noncurrent $21,220 USD -85%
Liabilities $6,056,994 USD 145%
Retained Earnings (Accumulated Deficit) $117,877,702 USD -29%
Stockholders' Equity Attributable to Parent $73,174,166 USD -13%
Liabilities and Equity $79,231,160 USD -8.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,028,381 USD -15%
Net Cash Provided by (Used in) Financing Activities $15,268 USD
Net Cash Provided by (Used in) Investing Activities $33,948 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 91,879,177 shares 23%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,077,597 USD -16%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $76,938,183 USD -9.3%
Deferred Tax Assets, Valuation Allowance $24,759,392 USD 49%
Deferred Tax Assets, Gross $25,005,599 USD 49%
Operating Lease, Liability $100,000 USD -50%
Payments to Acquire Property, Plant, and Equipment $33,948 USD
Operating Lease, Liability, Current $118,980 USD 14%
Deferred Tax Assets, Operating Loss Carryforwards $9,318,875 USD 20%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $190,959,989 USD 9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $4,055 USD 58%
Share-based Payment Arrangement, Expense $1,237,733 USD 43%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%